HK:3681 Stock Latest News
Company AnnouncementsSinoMab Clarifies Use of 2025 Share Proceeds and Share Award Details1M ago3681
Company AnnouncementsSinoMab Shareholders Unanimously Back Disposal Deal at Extraordinary Meeting1M ago3681
Company AnnouncementsSinoMab Advances Antibody Pipeline With New Trials and Preclinical Milestones2M ago3681
Company AnnouncementsSinoMab Seeks Shareholder Approval to Sell Suzhou Industrial Property for RMB280 Million2M ago3681
Company AnnouncementsSinoMab Schedules Board Meeting to Approve 2026 Interim Results2M ago3681
Company AnnouncementsSinoMab Sets September EGM on Major Suzhou Facility Disposal2M ago3681
Company AnnouncementsSinoMab BioScience Clarifies Board and Committee Roles in Governance Update2M ago3681
Company AnnouncementsSinoMab Delays Dispatch of Circular on Major Suzhou Asset Disposal2M ago3681
Company AnnouncementsSinoMab Delays Circular on Major Suzhou Property Disposal3M ago3681
Company AnnouncementsSinoMab Grants 18 Million Share Options to Executive and Staff3M ago3681
Company AnnouncementsSinoMab to Sell Suzhou Biologics Facility in RMB280 Million Deal3M ago3681
Company AnnouncementsSinoMab Elevates COO Fang Liang to Executive Director to Bolster Biotech Strategy4M ago3681- Company AnnouncementsSinoMab Shareholders Unanimously Approve All Resolutions, Add New Non-Executive Director4M ago3681
- Company AnnouncementsSinoMab Showcases Promising Preclinical Data for Novel Antibody in Alopecia and Vitiligo5M ago3681
- Company AnnouncementsSinoMab Sets 2026 AGM to Renew Board, Auditor and Share Capital Mandates6M ago3681
Company AnnouncementsSinoMab Starts Phase 2 Trial of IL‑25 Antibody SM17 in Chinese Atopic Dermatitis Patients7M ago3681
Company AnnouncementsSinoMab Updates Board and Committee Structure to Clarify Governance Roles7M ago3681Company AnnouncementsSinoMab BioScience Announces Resignations of Two Non-Executive Directors7M ago3681